Virax Biolabs Group Ltd [NASDAQ: VRAX] loss -3.54% or -0.04 points to close at $0.99 with a heavy trading volume of 181914 shares.
The daily chart for VRAX points out that the company has recorded -41.56% loss over the past six months.
If we look at the average trading volume of 256.76K shares, VRAX reached to a volume of 181914 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here is what top equities market gurus are saying about Virax Biolabs Group Ltd [VRAX]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for VRAX shares is $3.00 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on VRAX stock is a recommendation set at 1.00. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
H.C. Wainwright have made an estimate for Virax Biolabs Group Ltd shares, keeping their opinion on the stock as Buy, with their previous recommendation back on March 31, 2025.
The Average True Range (ATR) for Virax Biolabs Group Ltd is set at 0.13, with the Price to Sales ratio for VRAX stock in the period of the last 12 months amounting to 53.90. The Price to Book ratio for the last quarter was 0.30, with the Price to Cash per share for the same quarter was set at 1.68.
Trading performance analysis for VRAX stock
Virax Biolabs Group Ltd [VRAX] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 13.35. With this latest performance, VRAX shares dropped by -19.23% in over the last four-week period, additionally sinking by -41.56% over the last 6 months – not to mention a rise of 52.71% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for VRAX stock in for the last two-week period is set at 39.74, with the RSI for the last a single of trading hit 42.08, and the three-weeks RSI is set at 39.38 for Virax Biolabs Group Ltd [VRAX]. The present Moving Average for the last 50 days of trading for this stock 1.3900, while it was recorded at 1.0427 for the last single week of trading, and 1.9359 for the last 200 days.
Virax Biolabs Group Ltd [VRAX]: A deeper dive into fundamental analysis
Virax Biolabs Group Ltd’s liquidity data is similarly interesting compelling, with a Quick Ratio of 11.40 and a Current Ratio set at 11.58.
Virax Biolabs Group Ltd [VRAX]: An earnings per share (EPS) analysis
The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for VRAX. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Virax Biolabs Group Ltd go to 41.71%.
An analysis of Institutional ownership at Virax Biolabs Group Ltd [VRAX]
There are presently around $6.72%, or 7.19%% of VRAX stock, in the hands of institutional investors. The top three institutional holders of VRAX stocks are: VIRTU FINANCIAL LLC with ownership of 28058.0 shares, which is approximately 1.3984%. HRT FINANCIAL LP, holding 25672.0 shares of the stock with an approximate value of $$29000.0 in VRAX stocks shares; and HRT FINANCIAL LP, currently with $$12761.0 in VRAX stock with ownership which is approximately 0.5483%.
